As exclusivity is granted based on the staggering costs of clearing the FDA steeplechase, low-cost consumer options have a way of disappearing: “KV priced Makena like so many other branded drugs at $1,500 per injection. Had there been no compounding market at about $15 per injection, virtually no one’s sense of propriety would have been ruffled and perhaps no one would have even noticed.” [Charles Hooper, Medical Progress Today]

Filed under: FDA